Antigen-Specific Killer Polylactic-Co-Glycolic Acid (PLGA) Microspheres Can Prolong Alloskin Graft Survival in a Murine Model

References

• Apicella C, Roldan ER, Chiappetta DA, et al. (2009). Asymmetric IgG antibodies induced by different immunotherapies in murine model of allergy. Immunol Invest, 38, 572–88
   PubMed Web of Science ®Google Scholar
• Bhat AA, Seth RK, Kumar S, et al. (2010). Induction of cell-mediated immune responses to peptide antigens of P. vivax in microparticles using intranasal immunization. Immunol Invest, 39, 483–99
   PubMed Web of Science ®Google Scholar
• Buonocore S, Paulart F, Le Moine A, et al. (2003). Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood, 101, 1469–76
   PubMed Web of Science ®Google Scholar
• Chuang YH, Suen JL, Chiang BL. (2006). Fas-ligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma. J Mol Med, 84, 595–603
   PubMed Web of Science ®Google Scholar
• Constantin CM, Bonney EE, Altman JD, Strickland OL. (2002). Major histocompatibility complex (MHC) tetramer technology: An evaluation. Biol Res Nurs, 4, 115–27
   PubMedGoogle Scholar
• Dal Porto J, Johansen TE, Catipovic B, et al. (1993). A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA, 90, 6671–5
   PubMed Web of Science ®Google Scholar
• Drachman DB, Wu JM, Miagkov A, et al. (2003). Specific immunotherapy of experimental myasthenia by genetically engineered APCs: The “guided missile” strategy. Ann NY Acad Sci, 998, 520–32
   PubMed Web of Science ®Google Scholar
• Dulat HJ, von Grumbkow C, Baars W, et al. (2001). Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol, 31, 2217–26
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Rahim F. (2014). Recent immunomodulatory strategies in transplantation. Immunol Invest, 43, 829–37
   PubMed Web of Science ®Google Scholar
• Elhalel MD, Huang JH, Schmidt W, et al. (2003). CTLA-4: FasL induces alloantigen-specific hyporesponsiveness. J Immunol, 170, 5842–50
   PubMed Web of Science ®Google Scholar
• Fleck M, Zhang HG, Kern ER, et al. (2001). Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum, 44, 964–73
   PubMed Web of Science ®Google Scholar
• Garrod KR, Cahalan MD. (2008). Murine skin transplantation. J Vis Exp, pii, 634
   Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. (2005). The B7 family revisited. Annu Rev Immunol, 23, 515–48
   PubMed Web of Science ®Google Scholar
• Han H, Peng JR, Chen PC, et al. (2011). A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro. Biochem Biophys Res Commun, 411, 530–5
   PubMed Web of Science ®Google Scholar
• Hermans IF, Ritchie DS, Yang J, et al. (2000). CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol, 164, 3095–101
   PubMed Web of Science ®Google Scholar
• Hess PR, Barnes C, Woolard MD, et al. (2007). Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood, 109, 3300–7
   PubMed Web of Science ®Google Scholar
• Hoves S, Krause SW, Herfarth H, et al. (2004). Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. Immunobiology, 208, 463–75
   PubMed Web of Science ®Google Scholar
• Hoves S, Krause SW, Schutz C, et al. (2006). Monocyte-derived human macrophages mediate anergy in allogeneic T cells and induce regulatory T cells. J Immunol, 177, 2691–8
   PubMed Web of Science ®Google Scholar
• Kappel BJ, Pinilla-Ibarz J, Kochman AA, et al. (2006). Remodeling specific immunity by use of MHC tetramers: Demonstration in a graft-versus-host disease model. Blood, 107, 2045–51
   PubMed Web of Science ®Google Scholar
• Kuhns ST, Pease LR. (1998). A region of conformational variability outside the peptide-binding site of a class I MHC molecule. J Immunol, 161, 6745–50
   PubMed Web of Science ®Google Scholar
• Kusuhara M, Matsue K, Edelbaum D, et al. (2002). Killing of naive T cells by CD95L-transfected dendritic cells (DC): In vivo study using killer DC-DC hybrids and CD4(+) T cells from DO11.10 mice. Eur J Immunol, 32, 1035–43
   PubMed Web of Science ®Google Scholar
• Maile R, Wang B, Schooler W, et al. (2001). Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol, 167, 3708–14
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3, 1377–97
   PubMed Web of Science ®Google Scholar
• Matsue H, Matsue K, Kusuhara M, et al. (2001). Immunosuppressive properties of CD95L-transduced “killer” hybrids created by fusing donor- and recipient-derived dendritic cells. Blood, 98, 3465–72
   PubMed Web of Science ®Google Scholar
• Prakken B, Wauben M, Genini D, et al. (2000). Artificial antigen-presenting cells as a tool to exploit the immune ‘synapse’. Nat Med, 6, 1406–10
   PubMed Web of Science ®Google Scholar
• Quah BJC, Parish CR. (2012). New and improved methods for measuring lymphocyte proliferation in vitro and in vivo using CFSE-like fluorescent dyes. J Immunol Methods, 379, 1–14
   PubMed Web of Science ®Google Scholar
• Schutz C, Fleck M, Mackensen A, et al. (2008). Killer artificial antigen-presenting cells: A novel strategy to delete specific T cells. Blood, 111, 3546–52
   PubMed Web of Science ®Google Scholar
• Schutz C, Hoves S, Halbritter D, et al. (2011). Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells. Immunology, 133, 115–22
   PubMed Web of Science ®Google Scholar
• Schutz C, Oelke M, Schneck JP, et al. (2010). Killer artificial antigen-presenting cells: The synthetic embodiment of a ‘guided missile’. Immunotherapy, 2, 539–50
   PubMed Web of Science ®Google Scholar
• Shen C, Chang CC, Zhang J, et al. (2006). Structural and functional characterization of peptide-beta2m fused HLA-A2/MART1(27-35) complexes. Biochem Biophys Res Commun, 342, 57–65
   PubMed Web of Science ®Google Scholar
• Shen C, He Y, Cheng K, et al. (2011). Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation. Immunol Lett, 138, 144–55
   PubMed Web of Science ®Google Scholar
• Whartenby KA, Straley EE, Kim H, et al. (2002). Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood, 100, 3147–54
   PubMed Web of Science ®Google Scholar
• Wolfe T, Asseman C, Hughes A, et al. (2002). Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol, 169, 4867–72
   PubMed Web of Science ®Google Scholar
• Yolcu ES, Askenasy N, Singh NP, et al. (2002). Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity, 17, 795–808
   PubMed Web of Science ®Google Scholar
• Yuan RR, Wong P, McDevitt MR, et al. (2004). Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood, 104, 2397–402
   PubMed Web of Science ®Google Scholar